Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. is an orphan‑focused, neuropsychiatric biopharmaceutical company based in Devon, Pennsylvania. It pioneers transdermal cannabinoid therapies for rare neurological disorders, notably developing Zygel (ZYN002), a permeation‑enhanced cannabidiol gel for conditions like Fragile X and 22q11.2 deletion syndrome.
Address: 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462
Phone: (484) 539-9800
-
Devon-Based CBD Developer Plans Reverse Stock Split
A Devon pharmaceutical company is working on cannabinoid therapies to treat genetic conditions. In the meantime, Zynerba Pharmaceuticals is planning a reverse stock split by…
-
As Stock Market Hits Low Point, These Chester County Companies Saw Their Stocks Drop the Most
At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…
-
This Devon-Based Pharmaceutical Company Aims to Treat Autism with CBD
Zynerba Pharmaceuticals, a clinical-stage pharmaceutical company based in Devon, is testing a CBD gel to help treat autism, writes Queen Muse for Philadelphia magazine. The…
-
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Devon-based Zynerba Pharmaceuticals saw its shares surge after it received a U.S. patent for its cannabidiol (CBD) gel to treat Autism Spectrum Disorders, writes Sam…
-
Synthetic Cannabidiol Drug from Devon-Based Zynerba Pharmaceuticals Now on the ‘Fast Track’
Devon-based Zynerba Pharmaceuticals has received “Fast Track” status from the FDA for its synthetic cannabidiol drug intended to treat symptoms associated with Fragile X, writes…
-
Devon-Based Developer of Synthetic Cannabinoid Therapies Narrows Its Focus
Devon’s Zynerba Pharmaceuticals, which develops synthetic cannabinoid therapies, is focusing on several rare and near-rare neurological and psychiatric disorders that have unmet medical needs, writes…
-
Devon’s Zynerba Pharmaceuticals Delays Human Testing for Marijuana Pain Patch
For Devon’s Zynerba Pharmaceuticals, the switch to a smaller patch for pain treatment using a synthetic cannabinoid has bumped back the company’s target date for…
-
Zynerba Extending Testing After Successful Trial of its Synthetic Cannabinoid Gel
It has been a good week for Zynerba Pharmaceuticals, as the Devon based company received very positive results from the first phase of testing on…
-
Devon Medical Marijuana Startup Zynerba Pharmaceuticals Set To Go Public
A synthetic medical marijuana pioneer recently transplanted in Devon is experiencing an exciting high this week as it prepares to go public with 10 years…
-
Zynerba Taps Richard Baron As It Prepares To Bring Synthetic Cannabinoid Therapies To Market
Richard A. Baron is now vice president and chief financial officer at Zynerba Pharmaceuticals, Inc. of Radnor, a specialty pharmaceutical company that has invested $13…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
